Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting

BACKGROUND: Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor currently dosed by 8-hour intervals to treat complicated and multidrug-resistant Pseudomonas aeruginosa infections in inpatients. This dosing strategy limits the ability to transition patients to outpatient antim...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Bruce M, Huelfer, Kathryn, Bland, Christopher M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report (Fast Track-FIDSA Members Only)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000837/
https://www.ncbi.nlm.nih.gov/pubmed/32042849
http://dx.doi.org/10.1093/ofid/ofaa014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000837/
https://www.ncbi.nlm.nih.gov/pubmed/32042849
http://dx.doi.org/10.1093/ofid/ofaa014

Ejemplares similares